Cargando…

The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review

BACKGROUND AND OBJECTIVE: The survival benefit of induction therapy for non-small cell lung cancer (NSCLC) remains controversial. Recently, the outcomes of systemic therapy for NSCLC have dramatically changed with the advent of molecular target drugs and immune checkpoint inhibitors (ICIs). The pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinohara, Shuichi, Takahashi, Yusuke, Masago, Katsuhiro, Matsushita, Hirokazu, Kuroda, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992625/
https://www.ncbi.nlm.nih.gov/pubmed/36910085
http://dx.doi.org/10.21037/jtd-22-957
_version_ 1784902354996297728
author Shinohara, Shuichi
Takahashi, Yusuke
Masago, Katsuhiro
Matsushita, Hirokazu
Kuroda, Hiroaki
author_facet Shinohara, Shuichi
Takahashi, Yusuke
Masago, Katsuhiro
Matsushita, Hirokazu
Kuroda, Hiroaki
author_sort Shinohara, Shuichi
collection PubMed
description BACKGROUND AND OBJECTIVE: The survival benefit of induction therapy for non-small cell lung cancer (NSCLC) remains controversial. Recently, the outcomes of systemic therapy for NSCLC have dramatically changed with the advent of molecular target drugs and immune checkpoint inhibitors (ICIs). The present review was conducted to investigate the outcomes of induction therapy with reference to randomized control trials (RCTs). METHODS: We reviewed RCTs and ongoing clinical trials between 1990 and 2022 using relevant databases: PubMed, Web of Science, and EMBASE database. We investigated the outcomes of induction therapy. KEY CONTENT AND FINDINGS: Induction therapy was associated with longer overall survival in comparison to surgery alone in several RCTs for stage III disease. However, its benefit in early-stage (I–II) disease was unclear. Regarding induction chemotherapy and chemoradiotherapy, the safety and survival outcomes did not differ between the two arms. Epidermoid growth factor receptor (EGFR) tyrosine kinase inhibitors as induction therapy in patients with proven EGFR mutations may be a sufficient choice for the improvement of overall survival. In ongoing single arm clinical trials and a randomized control study, the administration of ICIs as induction therapy was associated with a good pathological response and satisfactory safety, which will lead to a better survival outcome. Long-term observation is needed to evaluate the toxicity and survival impact of induction therapy with ICIs. CONCLUSIONS: Induction chemotherapy and EGFR-TKIs for stage IIIA NSCLC may contribute to the improvement of survival outcomes although the effect of systemic therapy on stage I-II remains controversial. ICIs may be considered as a valuable treatment option because of their feasibility and safety for induction therapy.
format Online
Article
Text
id pubmed-9992625
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-99926252023-03-09 The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review Shinohara, Shuichi Takahashi, Yusuke Masago, Katsuhiro Matsushita, Hirokazu Kuroda, Hiroaki J Thorac Dis Review Article BACKGROUND AND OBJECTIVE: The survival benefit of induction therapy for non-small cell lung cancer (NSCLC) remains controversial. Recently, the outcomes of systemic therapy for NSCLC have dramatically changed with the advent of molecular target drugs and immune checkpoint inhibitors (ICIs). The present review was conducted to investigate the outcomes of induction therapy with reference to randomized control trials (RCTs). METHODS: We reviewed RCTs and ongoing clinical trials between 1990 and 2022 using relevant databases: PubMed, Web of Science, and EMBASE database. We investigated the outcomes of induction therapy. KEY CONTENT AND FINDINGS: Induction therapy was associated with longer overall survival in comparison to surgery alone in several RCTs for stage III disease. However, its benefit in early-stage (I–II) disease was unclear. Regarding induction chemotherapy and chemoradiotherapy, the safety and survival outcomes did not differ between the two arms. Epidermoid growth factor receptor (EGFR) tyrosine kinase inhibitors as induction therapy in patients with proven EGFR mutations may be a sufficient choice for the improvement of overall survival. In ongoing single arm clinical trials and a randomized control study, the administration of ICIs as induction therapy was associated with a good pathological response and satisfactory safety, which will lead to a better survival outcome. Long-term observation is needed to evaluate the toxicity and survival impact of induction therapy with ICIs. CONCLUSIONS: Induction chemotherapy and EGFR-TKIs for stage IIIA NSCLC may contribute to the improvement of survival outcomes although the effect of systemic therapy on stage I-II remains controversial. ICIs may be considered as a valuable treatment option because of their feasibility and safety for induction therapy. AME Publishing Company 2023-02-02 2023-02-28 /pmc/articles/PMC9992625/ /pubmed/36910085 http://dx.doi.org/10.21037/jtd-22-957 Text en 2023 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Shinohara, Shuichi
Takahashi, Yusuke
Masago, Katsuhiro
Matsushita, Hirokazu
Kuroda, Hiroaki
The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review
title The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review
title_full The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review
title_fullStr The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review
title_full_unstemmed The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review
title_short The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review
title_sort beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992625/
https://www.ncbi.nlm.nih.gov/pubmed/36910085
http://dx.doi.org/10.21037/jtd-22-957
work_keys_str_mv AT shinoharashuichi thebeginningofaneweraininductiontreatmentforoperablenonsmallcelllungcanceranarrativereview
AT takahashiyusuke thebeginningofaneweraininductiontreatmentforoperablenonsmallcelllungcanceranarrativereview
AT masagokatsuhiro thebeginningofaneweraininductiontreatmentforoperablenonsmallcelllungcanceranarrativereview
AT matsushitahirokazu thebeginningofaneweraininductiontreatmentforoperablenonsmallcelllungcanceranarrativereview
AT kurodahiroaki thebeginningofaneweraininductiontreatmentforoperablenonsmallcelllungcanceranarrativereview
AT shinoharashuichi beginningofaneweraininductiontreatmentforoperablenonsmallcelllungcanceranarrativereview
AT takahashiyusuke beginningofaneweraininductiontreatmentforoperablenonsmallcelllungcanceranarrativereview
AT masagokatsuhiro beginningofaneweraininductiontreatmentforoperablenonsmallcelllungcanceranarrativereview
AT matsushitahirokazu beginningofaneweraininductiontreatmentforoperablenonsmallcelllungcanceranarrativereview
AT kurodahiroaki beginningofaneweraininductiontreatmentforoperablenonsmallcelllungcanceranarrativereview